Covid-19: Vaccine booster study begins in Cambridge

Covid-19: Vaccine booster study begins in Cambridge

6/14/2021 5:03:00 PM

Covid-19: Vaccine booster study begins in Cambridge

The Cov-Boost study is testing seven vaccines to see which works best as a third dose.

John Hodgson said he hoped the trial could help "thousands, even millions, of people".Mr Hodgson, 80, from Sawston near Cambridge, said he had been one of the "lucky ones" when he got his first two jabs in December and January."I feel privileged," he said. "We will all benefit in the end.

Justice Department advises Biden administration to hand over Trump tax returns to Congress Trump's tax returns must be released to Congress, Justice Department says DOJ says Congress has authority to see Trump's taxes

"If we can learn from this... I would have done my bit."image copyrightRichard Westcott/BBCimage captionAudrey Philip said the pandemic has been worse than the second world war as people have been stuck in their homes for so longAudrey Philip, from Dry Drayton, said at 88 years old "there is very little I can do, so I thought I should be putting something back to help research".

"I think it [the pandemic] is worse than the war as people are so confined," she said.image copyrightimage captionAndy Nightingale has worked as a volunteer for the ambulance service during the pandemicAndy Nightingale was one of the first people in the country to get vaccinated because of his work with the volunteer ambulance service. headtopics.com

The 51-year-old said the trial was "very important"."I just want to help where I can," he added. "I'm just hoping everyone else can benefit as a result."Researchers at the National Institute for Health Research (NIHR) Cambridge Clinical Research Facility has been recruiting local volunteers, all of whom must be aged 30 or over and have already had two doses of a vaccine.

image captionProf Krishna Chatterjee said it was an "exciting opportunity to now work on a study to determine the effects of a third 'booster' dose"They will each get one booster, either a placebo or a vaccine, which could be a different brand to the one they were originally vaccinated with.

Read more: BBC Health News »

Candace Cameron Bure apologized after posting this TikTok video - CNN Video

Actress Candace Cameron Bure apologized to fans for a TikTok where she holds a Bible and lip syncs to a Lana Del Rey song.

Dr fernando Gomes Pinto is a world class sgrammer. Scam took my money 84,250 USD He's on CNN Brazil I want him to transfer my money back.

Novavax Says Its COVID-19 Vaccine Is Highly Effective In Large StudyWhile demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical.

Novavax Says Its COVID-19 Vaccine Is Highly Effective In Large StudyWhile demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical. it's low in US because of anti-vaccine crowd

As COVID-19 cases wane, vaccine-lagging areas still see riskNew COVID-19 cases are declining across the most of the country, even in some states with vaccine-hesitant populations.

Novavax COVID-19 vaccine more than 90% effective in U.S. trialNovavax Inc (NVAX.O) on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.

Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trialJUST IN: Novavax says its coronavirus vaccine has an overall efficacy of 90.4% and was 'generally well-tolerated' in a Phase 3 trial in the US and Mexico Generally well tolerated... Well that could have been worded better Great news Additional analysis of the trial are ongoing ,, according to the company ,and will be submitted to peer reviewed journals for publication.

Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.